Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825930 | 0.91 | KLKB1 (0.61) | KLKB1F10PRSS1PRSS2PRSS3 | |
| SCHEMBL17064862 | 0.91 | KLKB1 (0.61) | KLKB1F10PRSS1PRSS2PRSS3 | |
| SCHEMBL31067667 | 0.91 | KLKB1 (0.61) | KLKB1F10PRSS1PRSS2PRSS3 | |
| SCHEMBL18623008 | 0.89 | KLKB1 (0.47) | KLKB1MAPTF2F10PRSS1 | |
| SCHEMBL18623013 | 0.88 | KLKB1 (0.60) | KLKB1MAPTF2F10PRSS1 | |
| SCHEMBL18623004 | 0.88 | KLKB1 (0.58) | KLKB1MAPTF2F10PRSS1 | |
| SCHEMBL18623020 | 0.86 | KLKB1 (0.42) | KLKB1MAPTF2F10PRSS1 | |
| SCHEMBL18623024 | 0.84 | KLKB1 (0.66) | KLKB1 | |
| SCHEMBL18623015 | 0.84 | F2 (0.61) | KLKB1F2F10PRSS1PRSS2 | |
| SCHEMBL18623039 | 0.83 | KLKB1 (0.53) | KLKB1F2F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAPT 3007/4885F2 24/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAPT 2830/4885F2 28/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAPT 2685/4885F2 33/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAPT 2984/4885F2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.